Liver Cancer Updates

Experts who treat gastrointestinal malignancies discuss the appropriateness for lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma following the release of phase 1b data presented at the ASCO 2020 Virtual Meeting.

Data from an early-phase study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma is discussed. (ClinicalTrials.gov Identifier: NCT03006926)